

Nationwide Pneumococcal Conjugate Vaccine Drive

Why in News

Recently, the Union Health Minister has launched a nationwide expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) with an aim to reduce under 5 mortalities caused due to pneumonia.

- It was launched under the <u>Universal Immunisation Programme (UIP)</u> as a part of <u>'Azadi ka Amrit Mahotsay</u>'.
- It was for the first time in the country that PCV would be available for universal use.

Key Points

- Pneumococcal Conjugate Vaccine (PCV):
 - A Pneumococcal Conjugate Vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae, used in children and studied in patients with impaird immune system for the prevention of pneumococcal disease.
 - Conjugate vaccines are made using a combination of two different components.
- Pneumococcal Disease:
 - About: It is a bacterial infection caused by Streptococcus pneumoniae, sometimes known as pneumococcus.
 - Symptoms: These bacteria can cause many types of illnesses, including pneumonia, which is an infection of the lungs. Pneumococcal bacteria are one of the most common causes of pneumonia.
 - **Vulnerable Population**: Children under 2 years of age, people with certain medical conditions, adults 65 years or older, and cigarette smokers are at the highest risk.
 - Status in India: In India, around 16% of deaths among children occur due to pneumonia.
 - **Pneumonia is contagious** and can be spread through coughing or sneezing. It can also be spread through fluids, like blood during childbirth, or from contaminated surfaces.
- Universal Immunisation Programme (UIP):
 - Launch:
 - The **Immunization Programme in India** was introduced in 1978 as **'Expanded Programme of Immunization (EPI)** by the Ministry of Health and Family Welfare.
 - In 1985, the Programme was modified as 'Universal Immunization Programme (UIP)'.
 - Objectives of the Programme:
 - Rapidly increasing immunization coverage,
 - · Improving the quality of services,

- Establishing a reliable cold chain system to the health facility level,
- Introducing a district-wise system for monitoring of performance, and
- Achieving self-sufficiency in vaccine production.

• Features:

- **UIP prevents mortality and morbidity** in children and pregnant women **against 12 vaccine-preventable diseases.** But in the past, it was seen that the increase in immunization coverage had slowed down and it increased at the rate of 1% per year between 2009 and 2013.
 - Nationally against 10 diseases <u>Diphtheria</u>, Pertussis, Tetanus, <u>Polio</u>, <u>Measles</u>, Rubella, severe form of Childhood <u>Tuberculosis</u>, <u>Rotavirus</u> <u>diarrhea</u>, <u>Hepatitis B</u> and Meningitis & Pneumonia caused by Haemophilus Influenzae type B.
 - **Sub-nationally against 2 diseases** Pneumococcal Pneumonia and Japanese Encephalitis; of which Pneumococcal Conjugate vaccine has been nationally expanded, while JE vaccine is provided only in endemic districts.

ne Vision

- To accelerate the coverage, <u>Mission Indradhanush</u> was envisaged and implemented since 2015 to rapidly increase the full immunization coverage to 90%.
- Recently, the <u>Intensified Mission Indradhanush (IMI) 3.0 scheme</u> has been rolled out to cover children and pregnant women who missed routine immunisation during the Covid-19 pandemic.

Source: TH

PDF Reference URL: https://www.drishtiias.com/printpdf/nationwide-pneumococcal-conjugate-vaccine-drive